Effects of LRRK2 Inhibitors on Nigrostriatal Dopaminergic Neurotransmission
Related Experiment Video
Updated: Mar 10, 2026
Assaying the Kinase Activity of LRRK2 in vitro
Published on: January 18, 2012
Qi Qin1,2, Lian-Teng Zhi2, Xian-Ting Li3
1Department of Neurology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China.
Introduction:
Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most prevalent cause of familial and sporadic Parkinson's disease (PD). Because most pathogenic LRRK2 mutations result in enhanced kinase activity, it suggests that LRRK2 inhibitors may serve as a potential treatment for PD. To evaluate whether LRRK2 inhibitors are effective therapies for PD, it is crucial to know whether LRRK2 inhibitors will affect dopaminergic (DAergic) neurotransmission. However, to date, there is no study to investigate the impact of LRRK2 inhibitors on DAergic neurotransmission.
Aims:
To address this gap in knowledge, we examined the effects of three types of LRRK2 inhibitors (LRRK2-IN-1, GSK2578215A, and GNE-7915) on dopamine (DA) release in the dorsal striatum using fast-scan cyclic voltammetry and DA neuron firing in the substantia nigra pars compacta (SNpc) using patch clamp in mouse brain slices.
Results:
We found that LRRK2-IN-1 at a concentration higher than 1 μM causes off-target effects and decreases DA release, whereas GSK2578215A and GNE-7915 do not. All three inhibitors at 1 μM have no effect on DA release and DA neuron firing rate. We have further assessed the effects of the inhibitors in two preclinical LRRK2 mouse models (i.e., BAC transgenic hG2019S and hR1441G) and demonstrated that GNE-7915 enhances DA release and synaptic vesicle mobilization/recycling.
Conclusion:
GNE-7915 can be validated for further therapeutic development for PD.
Insights
LRRK2 inhibitors show promise for Parkinson's disease (PD) treatment. GNE-7915, a LRRK2 inhibitor, enhances dopamine release and synaptic function, validating its therapeutic potential for PD.
Area of Science:
- Neuroscience
- Pharmacology
- Genetics
Background:
- Mutations in leucine-rich repeat kinase 2 (LRRK2) are a leading cause of Parkinson's disease (PD).
- Enhanced LRRK2 kinase activity in PD suggests LRRK2 inhibitors as a potential therapeutic strategy.
- The impact of LRRK2 inhibitors on dopaminergic (DAergic) neurotransmission remains largely unexplored.
Purpose of the Study:
- To investigate the effects of LRRK2 inhibitors on dopamine release and DAergic neuron activity.
- To evaluate the therapeutic potential of specific LRRK2 inhibitors in preclinical PD models.
Main Methods:
- Utilized fast-scan cyclic voltammetry to measure dopamine release in mouse dorsal striatum.
- Employed patch clamp electrophysiology to assess DA neuron firing in the substantia nigra pars compacta.
- Tested LRRK2 inhibitors (LRRK2-IN-1, GSK2578215A, GNE-7915) in wild-type and LRRK2 mutant mouse models.
Main Results:
- LRRK2-IN-1 exhibited off-target effects and reduced dopamine release at concentrations >1 μM.
- GSK2578215A and GNE-7915 showed no adverse effects on dopamine release or DA neuron firing at 1 μM.
- GNE-7915 demonstrated enhanced dopamine release and improved synaptic vesicle dynamics in LRRK2 preclinical models.
Conclusions:
- GNE-7915 shows efficacy in enhancing dopaminergic function in preclinical models.
- GNE-7915 is a promising candidate for further therapeutic development for Parkinson's disease.
- LRRK2 inhibitors, particularly GNE-7915, warrant continued investigation for PD treatment.
More Related Videos
06:45Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
12:49Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
Published on: March 21, 2020
Related Concept Videos
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
01:29Drugs Affecting Neurotransmitter Synthesis
01:15Parkinson's Disease: Overview
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
01:37Neural Regulation
01:25Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...